Company Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.
Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2.
The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.
It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications.
The company was founded in 2005 and is headquartered in San Diego, California.
| Country | United States |
| IPO Date | Feb 13, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 101 |
| CEO | Dr. Linda Marbán Ph.D. |
Contact Details
Address: 10865 Road to the Cure San Diego, California United States | |
| Website | https://www.capricor.com |
Stock Details
| Ticker Symbol | CAPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001133869 |
| CUSIP Number | 14070B309 |
| ISIN Number | US14070B3096 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Linda Marbán Ph.D. | Co-Founder, President, Chief Executive Officer & Director |
| Anthony J. Bergmann M.B.A. | Chief Financial Officer & Corporate Treasurer |
| Catherine Lee Kelleher | Consultant |
| Dr. Frank Isaac Litvack FACC, M.D. | Executive Chairman of the Board |
| Dr. Kristi A. H. Elliott Ph.D. | Chief Science Officer |
| Karen G. Krasney | Executive Vice President, General Counsel & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 4 | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 22, 2024 | S-3 | Filing |
| Oct 17, 2024 | 424B5 | Filing |
| Oct 17, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 424B5 | Filing |